Michael Atkins
Directeur/Bestuurslid bij WEREWOLF THERAPEUTICS, INC.
Vermogen: 89 542 $ op 30-04-2024
Profiel
Michael B.
Atkins is currently the Director at the Melanoma Research Foundation.
He is also an Independent Director at Werewolf Therapeutics, Inc. starting in 2024.
Additionally, he holds the position of President at the Society For Immunotherapy of Cancer.
In 2002, he started working as a Professor at Harvard Medical School.
Dr. Atkins completed his undergraduate degree at Tufts University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-01-2024 | 14 419 ( 0.03% ) | 89 542 $ | 30-04-2024 |
Actieve functies van Michael Atkins
| Bedrijven | Functie | Begin |
|---|---|---|
| WEREWOLF THERAPEUTICS, INC. | Directeur/Bestuurslid | 04-01-2024 |
Melanoma Research Foundation
 Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Directeur/Bestuurslid | - |
| Harvard Medical School | Corporate Officer/Principal | 01-01-2002 |
Society For Immunotherapy of Cancer
 Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | President | - |
Opleiding van Michael Atkins
| Tufts University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Melanoma Research Foundation
Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Commercial Services |
Society For Immunotherapy of Cancer
Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |